Navigation Links
S1 Biopharma Expands Focus to Include Male Sexual Health
Date:5/13/2012

JERSEY CITY, N.J., May 14, 2012 /PRNewswire/ -- S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

The expansion into male sexual health represents S1 Biopharma's intent to take a comprehensive and holistic approach to treating HSDD, a clinical condition marked by persistent lack of desire, personal distress, and interpersonal difficulty.

"In the case of couples with one or both partners experiencing HSDD, there is a benefit to treating both genders together rather than treating one partner alone," said Nicolas G. Sitchon, CEO of S1 Biopharma. "S1P-205 and Lorexys—our drug for female HSDD—are perfect for this dual treatment approach."

With the development of S1P-205, S1 Biopharma is taking steps to address desire disparity between partners and dispelling the myth than men don't have problems with desire.

Targeting Desire Dysfunction
Desire dysfunction in males remains underserved by the biopharma community, despite the fact that PDE-5 inhibitor therapies like Viagra have a 43% non-response rate[1] —a rate suggesting that psychogenic factors deserve more attention than they're currently receiving.

Diverse research exists to support this view of desire dysfunction in males. A study of over a hundred female nurses in a relationship with a male partner found that 29.5% reported having more desire than their male partner.[2] 

An earlier study of a representative sample of non-geriatric U.S. adults found that 10.2% of men had "trouble maintaining/achieving an erection", while 15% of the men in the study  experienced a problematic "lack of interest in sex."[3] Put differently, the incidence of desire dysfunction in this sample of men was nearly one and a half times the incidence of erectile dysfunction (ED).

"Lack of desire—rather than some cardiovascular or physiological pathology—is a medical condition that can play a significant role in male sexual disorders," said Robert E. Pyke, Chief Medical Officer of S1 Biopharma. "PDE-5 inhibitor therapies are only half the story, and we hope to address the other half with S1P-205, helping men and their partners to have more fulfilling relationships."

About S1 Biopharma, Inc.
S1 Biopharma (formerly S1 Pharmaceuticals) is an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions.  S1 Biopharma's lead product, Lorexys, is the only non-hormonal therapy for HSDD in women. The company is also developing S1P-205 as the first and only therapy for HSDD in men. For additional information, visit www.s1biopharma.com.

[1] Sildenafil U.S. Labeling, 2012

[2] Sand M and Fisher WA, Rethinking Desire: Prevalence and Correlates of Desire Discordance in the Nurses Sexuality Study, 2007

[3] Laumann EO and Michael RT, Sex, Love, and Health in America, Chicago, 2000

Contact:
press@s1biopharma.com


'/>"/>
SOURCE S1 Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
2. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Equity Research on Most Popular Searches: Atmel, USG, Applied Materials, Sprint Nextel, Galena Biopharma, and Key Energy Services
8. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
9. Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry
10. PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes
11. Medtrack One View - A New More Powerful Biopharmaceutical Intelligence Tool Is Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/25/2017)... VIRGINIA (PRWEB) , ... April 25, 2017 , ... ... leading the way in unveiling cutting-edge birth defects research related to Zika virus ... by the world’s premier society for this important science. , The ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Buyers and ... recreational users to dispensaries and head shops –can’t help but be heartened by the ... the tell-tale cannabis odor aptly described as “skunk smell.” At last they can ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
(Date:4/25/2017)... ... , ... There is no better place in South Florida to undergo two ... May issue of Consumer Reports focused on heart health. , The magazine gave ... after coronary bypass and aortic valve replacement procedures. , Consumer Reports rated ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, ... continuation of its strategic partnership with and platinum sponsorship of Global Spine Outreach ... safe and effective management of complex spine deformity cases, particularly in children. , ...
Breaking Medicine News(10 mins):